Renowned physician and researcher Lynda Chin, MD, is The University of Texas System’s associate vice chancellor for health transformation and chief innovation officer for health affairs. Chin leads the UT System’s Institute for Health Transformation, which leverages, develops and deploys innovative, technology-enabled solutions to improve access and affordability of quality health care in Texas and beyond.
The Institute for Health Transformation is initially focused on Project DOC – Diabetes Obesity Control – an initiative to improve diabetes care and management in South Texas.
Prior to joining the UT System in 2015, Chin was the founding chair of Genomic Medicine and scientific director of the Institute for Applied Cancer Science at UT MD Anderson Cancer Center. Chin has made multiple scientific discoveries spanning the fields of transcription, telomere biology, and mouse models of human cancer and cancer genomics. She has won numerous distinguished honors for her contributions, including election to the prestigious Institute of Medicine (IOM) of the National Academies in 2012.
On October 6, 2016, Dr. Chin was appointed by the National Academies of Sciences, Engineering, and Medicine to a committee that will help guide U.S. policy on global health
When it comes to precision medicine, achieving the Holy Grail means cracking the genetic code, but when it comes to good health and happiness, the genome represents just one piece of the puzzle. It can provide insight, but by no means are a person’s genome and fate synonymous.
In this keynote, renowned physician and scientist Lynda Chin goes where few have yet to go and examines precision medicine from the individual or consumer perspective. She'll also discuss some of the products, technology, and services that may eventually revolutionize healthcare and tip the scale away from treatment and toward prevention.
As Chin will explain, prevention, healthcare’s ultimate goal, is the difference between using precision medicine to treat illness and empowering individuals with genetic insights to sidestep it.
Precision medicine is still a young and growing field and loaded with excitement and promise, but it’s also fraught with questions that, at the moment, have no clear answers.
For Example:
In this session, our panel of experts address these and other questions related to ethics, access, and affordability head on - and save plenty of time to take quesitons from the audience.
